APRIL 21-23, 2020

BOSTON, MA USA

Press Releases

Arrowhead Publishers Announces the Preliminary Speaker Faculty for 6th Annual Translational Microbiome Conference

November 7, 2019 – Minneapolis, MN – Arrowhead Publishers has announced the preliminary speaking faculty for the 6th Annual Translational Microbiome Conference. This conference, taking place April 21-23, 2020 in Boston, MA, will once again bring together the top researchers, leaders, companies and institutions in the field of microbiome science to share novel research, discuss issues relating to the commercialization of microbiome-based products and share new findings relating to the microbiome that are relevant for healthcare providers

This year’s conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome industry will have to recognize and navigate in order to successfully commercialize their products.

Key subject covered include:

• Research standards
• Manufacturing challenges
• Funding issues and challenges
• Therapeutic interventions undergoing clinical trials
• Novel microbiome science
• Gut-brain axis
• Microbiome sampling and diagnostics

For more information on the conference, visit www.microbiomeconference.com.

Speakers Include:
• Rachel Clemens, Ph.D., Commercial Innovation Manager, Life Science Lead, ISS US National Lab, Center for Advancement in Science in Space
• Lynne Elmore, Ph.D., Director, Translational Cancer Research Program, American Cancer Society
• Garth Ehrlich, Ph.D., Professor of Microbiology & Immunology, Professor of Otolaryngology - Head and Neck Surgery, Drexel University College of Medicine
• Wendy Garrett, Ph.D., Professor of Immunology and Infectious Diseases, Department of Immunology and Infectious Diseases, Department of Genetics and Complex Diseases, Department of Medicine, Harvard Medical School
• Momo Vuyisch, Ph.D., Chief Scientific Officer, Viome
• Shahram Lavasani, Ph.D., Founder, CEO/CSO, Immune Biotech
• Scott Jackson, Ph.D., Group Leader, Complex Microbial Systems, NIST
• Nancy Caralla, Founding President, Executive Director, C Diff Foundation
• Rachel Teitelbaum, Ph.D., Chief Executive Officer, Hervana
• Sonia Timberlake, Ph.D., Vice President of Research, Finch Therapeutics
• Dae-Wook Kang, Ph.D., Assistant Professor, Department of Civil & Environmental Engineering, University of Toledo
• Sameer Sonkusale, Ph.D., Professor of Electrical and Computer Engineering, Professor of Biomedical Engineering (adjunct), Director/Principal Investigator, Nano Lab, Tufts University
• Amy Feehan, Ph.D., Research Scientist, Ochsner Health System
• Ze'ev Ronai, Ph.D., Professor, Sanford Burnham Prebys Medical Discovery Institute
• Sangeeta Khare, Ph.D., Research Microbiologist, National Center for Toxicological Research, US Food and Drug Administration
• Lionel Breton, Ph.D., DSc, Scientific Director, L'Oreal Advanced Research, L'Oreal
• Anandh Babu Pon Velayutham, Ph.D., Associate Professor, Nutrition and Integrative Physiology, University of Utah
• Sara Ferrando Martinez, Ph.D., Research Scientist, AstraZeneca
• Julius Goepp, MD, Chief Executive Officer, Scaled Microbiomics
• Stewart Campbell, Ph.D., Vice President, Early Stage Development, Axial Biotherapeutics
• Gregg Silverman, MD, Professor of Medicine and Pathology, New York University School of Medicine
• Henri Haiser, Ph.D., Associate Scientific Director, GI Drug Discovery, Microbiome Sciences, Takeda
• Steve Schnittger, VP Global Microbiology R&D, Estee Lauder
• Mahmoud Ghannoum, Ph.D., EMBA, Professor, Department of Dermatology, Case Western Reserve University and University Hospitals Cleveland Medical Center

For the full list of speakers, CLICK HERE.


For more information, please contact:
John Waslif: Conference Director
Arrowhead Publishers
866-945-0263 ext 700
This email address is being protected from spambots. You need JavaScript enabled to view it.

Consumer track focuses on challenges and progress insights for companies creating microbiome-based consumer products and services

MINNEAPOLIS, March 6, 2018– Arrowhead Publishers released a parallel consumer track agenda for the 4th Annual Translational Microbiome Conference, April 18-20 in Boston. The conference is designed to bring together scientists at the forefront of microbiome research with pioneering business leaders at companies innovating microbiome-based medical solutions. The consumer track focuses on issues and learnings around direct-to-consumer product and service development, with an eye toward helping companies successfully (and efficiently) navigate from research and product innovation through regulation, commercialization and marketing.

“Microbiome research is delivering medical advancements across oncology, dermatology, inflammatory disorders, mental health and many related fields,” said John Waslif, Managing Director of Arrowhead Publishers. “The consumer track at our 4th Annual Translational Microbiome Conference provides a forum for companies to share best practices and process solutions. People want to take control of their health with access to the same science that’s making headlines in leading hospitals and medical labs, and we want to help speed the path to commercialization.”
As recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, scientists are discovering specific variables within the microbiome can profoundly impact a variety of conditions and diseases. To support exploration of translational consumer applications, consumer track presentations and discussion topics are broadly applicable, spanning multiple disease states and addressing issues common to companies in this space.


Consumer track sessions include:
Probiotic Hygiene and Care Response
Robin Temmerman, Ph.D., Chief Executive Officer, Chrisal, N.V.
Resistance of microbes to antibiotics and disinfectants is growing quickly, and allergies to chemical ingredients in cleaning and personal care products are on the rise. Rapid evolution in microbiological research has led to promising new probiotic hygiene technologies in the form of cleaning and personal care applications. For the past 15 years, Chrisal has invested to develop product solutions to widespread hygiene problems like biofilm, smell and infections. Dr. Temmerman will discuss the technology, mechanisms and benefits of probiotic hygiene and care.

Probiotic Home: The Future of Clean
John Howell, Industry Technology Specialist HHC, Novozymes
Consumers are increasingly aware of the microbiota surrounding them, and its integral role in their healthy lifestyle. They may not yet think of microbiota as a solution to what they spill on the floor. Yet, microorganisms, or probiotics, are nature’s oldest and most reliable cleaning crew. They work overtime to break down organics, for a deeper and longer-lasting “probiotic clean” than conventional chemicals. While the technology has long been used industrially, this concept has just recently started to resonate with consumers for application in their home environment. Mr. Howell will share several industrial and domestic cleaning scenarios in which microorganism-containing products are currently used, and he’ll predict future consumer cleaning habits and products that will selectively reinforce the microbiome of the home.

Panel Session: The Future of Probiotic Hygiene
Moderated by Joe Rubino, R&D Director for Reckitt Benckiser, panelists will include Matt Franken, Chief Executive Officer of Aunt Fannies; Robin Temmerman, Ph.D., Chief Executive Officer of Chrisal N.V. and other industry experts.

Early Life Microbiome: Connections between Nutritional Composition, Gastrointestinal Tract and the Brain
Maciej Chichlowski, Ph.D., PMP, Principal Scientist, Mead Johnson Nutrition (RB)
Optimal development of the microbiome is an emerging health benefit that’s likely to grow in consumer awareness and demand over time. Intestinal microbiota plays a role in metabolic, nutritional, physiological and immunological processes in the human body, and nutrition can affect gut microbiota colonization. Our research demonstrates that functional properties of early nutrition could benefit the microbiome and health. For instance, our studies have shown that early life diet with milk fat globule membrane and prebiotics promote immune, gut, and brain development and function.

Using Live Bacteria for Topical Skin Application: Regulatory Issues
Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
A growing body of data supports the importance of the skin microbiome in its role as a protective barrier against external influence. Products with live beneficial bacteria, or live biotherapeutic products (LBP’s), present the potential to improve symptoms of a multitude of skin disorders. Yet, safety of probiotic strains is of critical importance during the in vitro screening phase. By building up the safety documentation and quality controls in the production of products, Yun Probiotherapy was able to overcome EU regulatory issues and begin marketing their LBP line to consumers.

“Research in the microbiome presents tremendous potential to provide more effective treatments, cures, therapies and supplements,” said Waslif. “As investment opportunities are growing in this area, many companies are rapidly pursuing potential translational solutions. Therefore, sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings.”

View the full agenda for the 4th Annual Translational Microbiome Conference at www.microbiomeconference.com.
Sponsors and Exhibitors can showcase products and branding in an environment designed to facilitate professional networking. Learn more via www.microbiomeconference.com/sponsor-exhibit.

If you would like more information about this announcement or the 4th Annual Translational Microbiome Conference, please contact John Waslif, Managing Director at Arrowhead Publishers via email at This email address is being protected from spambots. You need JavaScript enabled to view it..

Conference topics will feature speakers and panels on animal models, bioinformatics challenges, intellectual property management, investment deals and approaches, pharma deals in the microbiome space, and the need for standards.

MINNEAPOLIS, November 28, 2017– Arrowhead Publishers unveils a growing roster of speakers for its 4th Annual Translational Microbiome Conference, to take place April 18-20 at Boston Marriott Long Wharf. The conference is designed to connect scientists at the forefront of microbiome research with pioneering companies investing to apply microbiome-based findings to innovate medical solutions. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others) attendees will have the opportunity to hear leading companies discuss the work they have underway and how they are meeting these challenges head-on to apply recent discoveries to a variety of disease processes, restoration of health, and improved outcomes.

“The topics and speakers for this year’s conference offer real education, insights and benefits our attendees can apply within their own organizations,” said John Waslif, Managing Director of Arrowhead Publishers and Conferences.

Speakers already confirmed for the conference include:
Peter Christey, Ph.D.
Co-Founder and Chief Executive Officer, General Automation Lab Technologies (GALT)
GALT’s innovative high-throughput microbiology platform can isolate multiple species from complex samples, such as soil and stool, allowing researchers to rapidly screen whole populations or engineered libraries. Dr. Christey is leveraging GALT tools to revolutionize how microbial studies are conducted, opening previously unreachable territories for scientists to explore.

Olga Danilchanka, Ph.D.
Microbiome Lead, Exploratory Science Center, Merck
Dr. Danilchanka serves as Microbiome Lead for Merck’s Exploratory Science Center, which focuses on the earliest stages of discovery research to better understand the underlying biology of human disease. Dr. Danilchanka’s team explores the most promising areas of emerging disease biology, including the role of the microbiome in disease, and works to gain new insights to inform Merck’s ongoing drug discovery.

Pinaki Panigrahi, M.D., Ph.D.
Professor, Department of Epidemiology and Pediatrics; Director of Center for Global Health and Development, University of Nebraska Medical Center, College of Public Health
An elected fellow of the Infectious Diseases Society of America, Dr. Panigrahi has studied neonatal and child health issues in developed nations and in the developing world. His expertise spans necrotizing enterocolitis, neonatal infections, diarrhea, malaria, birth asphyxia, prematurity, stillbirths and nutrition.

Mark Smith, Ph.D.,
Chief Executive Officer, Finch Therapeutics
Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse-engineer successful clinical experience with fecal transplantation. Rather than relying on in-vitro screening of a library of microbes, Finch uses this human-first discovery approach to identify strains that drive clinical outcomes and to develop therapies that deliver these microbial communities to patients.

Paul Giannasca, Ph.D.
Global Scientific Lead, GI Health, Nestle Health Science
Dr. Giannasca identifies and manages new nutritional and technological platforms relevant for the Gastrointestinal Health strategy for Nestle Health Science. Dr. Giannasca holds multiple U.S. patents covering active and passive immunization against Clostridium difficile disease and has published more than 25 papers in the areas of infectious diseases, vaccine development, active and passive immunization and vaccine-induced protection.

Other notable speakers participating in the 2018 conference include:
* David Kyle, Ph.D., Chief Scientific Officer, Evolve Biosystems
* Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
* Veronika Oudova, Chief Executive Officer, S Biomedic
* Travis Whitfill, Co-Founder and Chief Science Officer, Azitra
* Jennifer A. Wargo, M.D., Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center

New additions to the conference this year are topic-focused tracks for nutrition and for skin. A parallel consumer track will again be offered. Each track will be closely focused on key issues in its specific industry and the challenges common to companies trying to enter the microbiome space in that area.

Keynote address for the conference will be delivered by Emeran Mayer, M.D., Ph.D.
Director, UCLA Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress; Professor, Medicine; Professor, Psychiatry and Biobehavioral Sciences; Professor, Digestive Diseases/Gastroenterology; Co-Director, CURE: Digestive Diseases Research Center; Professor, Physiology, UCLA David Geffen School of Medicine
Dr. Mayer has a career-long interest in clinical and research aspects of brain-body interactions, with a focus on brain-gut interactions in health and disease. A widely recognized expert for functional GI disorders, he is also recognized as one of the leading investigators in the world of chronic visceral pain and of the brain-gut axis.

Further information about the 4th Annual Translational Microbiome Conference can be found at www.microbiomeconference.com.

Emeran Mayer, World-Renowned Gastroenterologist and Neuroscientist, to Deliver Keynote Address at 4th Annual Translational Microbiome Conference

MINNEAPOLIS, November 16, 2017– Dr. Emeran Mayer will deliver the keynote address at the 4th Annual Translational Microbiome Conference. Dr Mayer is a pioneer in researching brain-body interactions, focusing especially on brain-gut interactions in relation to health and disease. Besides being a widely recognized expert for functional GI disorders, he is also recognized as one of the leading investigators in the world of chronic visceral pain and of the brain-gut axis. Dr. Mayer’s keynote speech is closed to the public but open to registered conference attendees. The conference, which will be hosted by Arrowhead Publishers April 18-20 at the Boston Marriott Long Wharf, provides insight and collaboration opportunities between scientists at the forefront of microbiome research and pioneering companies investing to apply microbiome-based findings to innovate medical solutions.

“Not only is Dr. Mayer a leader in microbiome research,” said John Waslif, Managing Director of Arrowhead Publishers. “His career of investigative research has uncovered such pivotal findings that entire bodies of work are growing from that rich foundation. We are fortunate to hear firsthand about his newest research in April.”

A prolific research author, Dr. Mayer has published 210 original manuscripts in leading GI and Neuroscience journals, and 95 book chapters and reviews, has co-edited three books, and serves as Associate Editor of Gastroenterology. He is director of the Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress. Having served as president of the Functional Brain Gut group, he is also a regular member of the National Institute of Diabetes and Digestive and Kidney Diseases’ Clinical, Integrative and Molecular Gastroenterology study section. Dr. Mayer is currently engaged in research on sex differences in functional GI disorders, brain-bladder interactions, and brain imaging in IBS.

Just as Dr. Mayer’s findings span several medical specialties, his and other recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, and scientists are discovering specific variables within the microbiome that can profoundly impact a variety of conditions and diseases. To align with these findings and support exploration of translational applications, conference topics are broadly applicable, spanning multiple disease states, including oncology and dermatology, as well as inflammatory, cognitive and digestive disorders. In addition to Dr. Mayer’s keynote, progress from other groundbreaking researchers will be shared in conference sessions, and poster board presentations will offer direct access to discuss recent findings and current studies of key interest to the microbiome discussion.

The Translational Microbiome Conference will focus and build upon the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. Research in the microbiome represents tremendous potential to provide more effective therapies and supplements, and as investment opportunities are growing in this area, many companies are rapidly pursuing potential translational work. Sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings, and sessions will offer insight to how innovative companies are meeting challenges head-on to apply recent discoveries to a variety of disease processes.

Additional speakers for the 2018 Translational Microbiome Conference will be announced soon, and further information about the conference can be found at www.microbiomeconference.com.

Expert Panel Discussions to be Highlight of Agenda at the 3rd Annual Translational Microbiome Conference

Minneapolis, MN – February 15, 2017 – Arrowhead Publishers is pleased to announce that a variety of expert panel discussions have been announced for its upcoming 3rd Annual Translational Microbiome Conference. This event, which will take place April 11-13, 2017 in Boston, MA, will unite presenters and attendees from academia, industry, and the government to provide a multi-stakeholder perspective on the latest trends and developments in the microbiome space. For more information, visit: http://www.microbiomeconference.com.

The CEO of CosmosID Inc. Manoj Dadlani will lead the panel on bioinformatics tools for clinical applications in metagenomics, as well as challenges to overcome in the complex clinical and regulatory environments. Panelists will also discuss the dire need for robust bioinformatics tools that can address the complex clinical and regulatory environments.

Co-founder and CEO of Whole Biome, Dr. Colleen Cultcliffe, will be leading a panel discussion on the microbiome and its growing presence in the media. As new therapeutics are being developed, the microbiome industry must find ways to overcome the hype and unrealistic timelines that can be expected by the general public.

Mohan S. Iyer, CBO at Second Genome, will be moderating the panel on pharma companies working in the microbiome industry. He and the panelists will discuss the latest partnerships between the microbiome industry and pharma, and the deals outlook for 2017.

The “Strategies and Risks for Developing Comprehensive Patent and Licensing Strategies” panel will be led by Greg Sieczkiewicz, Managing Director at MPM Capital. This panel will analyze the various challenges and opportunities that organizations will experience when developing a patent portfolio in the microbiome therapeutics industry. They will also discuss what is necessary from a licensing perspective in order to create a successful pharma-biotech relationship.

Director of Research and Development of Reckitt Benckiser, Joe Rubino, will moderate the panel discussion “Time to Put the Hygiene Hypothesis to Rest?”

JP Benya, Vice President Commercial of Assembly Biosciences will lead the panel discussion on commercial challenges and opportunities in the microbiome-based therapeutics industry. By focusing on critical factors to consider when launching a MBT including regulatory considerations, customer expectations, and messaging implications, this panel will provide expert insight into the future of microbiome-based therapeutics.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Metagenomics Expert Rita Colwell to Deliver Keynote Address at Arrowhead’s 3rd Annual Translational Microbiome Conference

January 5, 2017 – Minneapolis, MN – The second keynote presentation at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will be given by Dr. Rita Colwell, Distinguished Professor at Johns Hopkins Bloomberg School of Public Health and founder of CosmosID. Her presentation will provide attendees with an overview of the application of metagenomics in improving knowledge of human biology, disease, and the environment. The conference will be taking place April 11-13, 2017 in Boston, MA. For more information, visit: http://www.microbiomeconference.com.

In an era of climate change, high-throughput sequencing and high-resolution bioinformatics are becoming increasingly powerful in microbiome studies, as well as the clinical management of infectious disease and environment. Dr. Colwell will provide several examples of using metagenomics in a clinical setting, including diarrheal disease, waterborne infections, and wastewater reuse.

Founded in 2008 by Dr. Colwell, CosmosID strives to make the world a healthier and safer place by delivering high-resolution bioinformatics for personalized monitoring of environmental bio threat agents in an accurate and cost-effective manner. For more information, visit: http://www.cosmosid.com.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Thought Leader in Microbiome Research Jack Gilbert to Present at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference

2 December 2016 – Minneapolis, MN – Jack Gilbert, the faculty director of The Microbiome Center and professor at the University of Chicago, has just been announced as the keynote speaker at Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference. This conference will once again unite top companies in the microbiome space working to successfully commercialize microbiome-based diagnostics and therapeutics. This conference will be taking place April 11-13, 2017 in Boston, MA. For more information on the conference, visit: http://www.microbiomeconference.com.

As the human microbiome is quickly demonstrating huge roles in the human ecosystem, scientists are discovering that changes in the microbiome have a huge impact on a variety of conditions and diseases. Dr. Gilbert will discuss the latest evidence of these mechanisms of interaction, and how we have started to disturb the delicate balance of immune-microbe equilibrium, thus impacting the development and function of our immune systems. By applying new strategies to identify how the microbial ecosystem correlates with diseases and treatment efficacy through Microbiome-Wide Association Studies (MWAS), microbiome studies are providing a new framework for facilitating patient care.

With an increasing awareness that many of our modern diseases are “lifestyle” related and more than 50% of current medications are ineffective for the people taking them, research in the microbiome presents a potential opportunity to provide more effective treatments, cures, therapies and supplements. Reflective of this trend is the fact that investment opportunities are growing in this area and many companies are rapidly moving towards potential translational work. 

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.